Procainamide Hydrochloride Injection
» Procainamide Hydrochloride Injection is a sterile solution of Procainamide Hydrochloride in Water for Injection. It contains not less than 95.0 percent and not more than 105.0 percent of the labeled amount of C13H21N3O·HCl.
Packaging and storage—
Preserve in single-dose or in multiple-dose containers, preferably of Type I glass.
Labeling—
Label it to indicate that the Injection is not to be used if it is darker than slightly yellow, or is discolored in any other way.
Identification—
It responds to the Thin-Layer Chromatographic Identification Test 
201
, 5 µL of the clear supernatant being used to prepare the Assay preparation in the Assay and 5 µL of the stock solution being used to prepare the Standard preparation in the Assay being applied to the plate, and a solvent system consisting of a mixture of ethyl acetate, methanol, and ammonium hydroxide (22:2:1) being used to develop the chromatogram.
201, 5 µL of the clear supernatant being used to prepare the Assay preparation in the Assay and 5 µL of the stock solution being used to prepare the Standard preparation in the Assay being applied to the plate, and a solvent system consisting of a mixture of ethyl acetate, methanol, and ammonium hydroxide (22:2:1) being used to develop the chromatogram.
Bacterial endotoxins 85—
It contains not more than 0.35 USP Endotoxin Unit per mg of procainamide hydrochloride.
85—
It contains not more than 0.35 USP Endotoxin Unit per mg of procainamide hydrochloride.
pH 791:
between 4.0 and 6.0.
791:
between 4.0 and 6.0.
Particulate matter 788:
meets the requirements under Small-volume injections.
788:
meets the requirements under Small-volume injections.
Other requirements—
It meets the requirements under Injections 1.
1.
Assay—
Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—
Prepare as directed in the Assay under Procainamide Hydrochloride.
Assay preparation—
Transfer an accurately measured volume of Injection, equivalent to about 500 mg of procainamide hydrochloride, to a 500-mL volumetric flask, dilute with methanol to volume, and mix. Transfer 5.0 mL of this stock solution to a 100-mL volumetric flask, reserving the remainder of the stock solution for the Identification test. Dilute with Mobile phase to volume, and mix.
Procedure—
Proceed as directed for Procedure in the Assay under Procainamide Hydrochloride. Calculate the quantity, in mg, of C13H21N3O·HCl in each mL of the Injection taken by the formula:
10,000(C / V)(rU / rS)
in which C is the concentration, in mg per mL, of USP Procainamide Hydrochloride RS in the Standard preparation, V is the volume, in mL, of Injection taken, and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information—
Please check for your question in the FAQs before contacting USP.
Chromatographic Column—
| Topic/Question | Contact | Expert Committee |
| Monograph | Sujatha Ramakrishna, Ph.D.
Scientist 1-301-816-8349 |
(MDCV05) Monograph Development-Cardiovascular |
| Reference Standards | Lili Wang, Technical Services Scientist 1-301-816-8129 RSTech@usp.org |
|
| 85 |
Radhakrishna S Tirumalai, Ph.D.
Senior Scientist 1-301-816-8339 |
(MSA05) Microbiology and Sterility Assurance |
USP32–NF27 Page 3389
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.